Anabolic-androgenic steroid (AAS) use refers to the non-medical ingestion of synthetic derivatives of testosterone to increase muscle mass, strength, and performance. The social context in the input suggests a “5 years” steroid “cure,” which is clinically important because long-term AAS exposure can profoundly disrupt the hypothalamic–pituitary–gonadal (HPG) axis. Normally, gonadotropin-releasing hormone (GnRH) from the hypothalamus stimulates pituitary luteinizing hormone (LH), which drives testicular Leydig cells to produce endogenous testosterone. Exogenous AAS increases androgenic signaling, suppresses GnRH and LH through negative feedback, and leads to testicular atrophy and impaired spermatogenesis.
A central medical concern is that cessation does not automatically restore normal endocrine function. Recovery time varies with duration, dose, specific compound, age, baseline fertility, and presence of comorbid conditions. After discontinuation, many individuals experience hypogonadism characterized by low libido, erectile dysfunction, fatigue, depressed mood, and decreased muscle mass. In laboratory terms, this may manifest as reduced testosterone, with compensatory changes in LH and follicle-stimulating hormone (FSH) depending on whether partial HPG axis function returns. Some people recover within months, while others—particularly after years of exposure—may develop prolonged or persistent hypogonadism that requires structured evaluation and, in some cases, medical management.
Cardiovascular risks are among the most consistently documented. AAS can worsen the lipid profile by decreasing high-density lipoprotein (HDL) and increasing low-density lipoprotein (LDL) and very-low-density lipoprotein patterns. They can also impair endothelial function, increase oxidative stress, and promote vascular inflammation. Clinically relevant outcomes include accelerated atherosclerosis, hypertension, left ventricular hypertrophy, arrhythmias, and increased risk of thrombotic events. Blood pressure changes may occur via sodium retention, altered renin–angiotensin signaling, and vascular remodeling. Long-term use also raises concern for cardiomyopathy, particularly when combined with other risk factors.
Beyond endocrine and cardiovascular effects, AAS use can affect metabolic and hepatic systems. Insulin sensitivity may worsen, contributing to impaired glucose regulation. Hepatic adverse effects depend on the route and compound: oral 17α-alkylated steroids are particularly associated with cholestasis, transaminitis, peliosis hepatis, and—rarely—hepatic tumors. Even injectable regimens can be associated with abnormalities in liver enzymes, though severity varies widely. Because symptom onset may be insidious, laboratory monitoring is critical for early detection.
Psychological and behavioral changes are also significant. Androgen exposure can influence neurotransmitter systems implicated in mood regulation (including serotonergic and dopaminergic pathways) and stress responsivity. Some users report irritability, insomnia, anxiety-like symptoms, and mood lability; during withdrawal or post-cycle periods, depressive symptoms can emerge as testosterone levels fall and neuroendocrine homeostasis destabilizes. While not every user develops clinically diagnosable disorders, the risk of mood and anxiety symptoms is clinically relevant, especially when persistent low androgen states coexist with sleep disruption and social or performance pressures.
Fertility impairment is another key domain. Suppressed LH and FSH reduce intratesticular testosterone and can lead to oligospermia or azoospermia. Semen parameters may improve after discontinuation, but recovery is not guaranteed and may take considerable time. Counseling regarding family planning is therefore essential, as is offering fertility assessment (e.g., semen analysis) rather than relying on subjective recovery.
A safety-oriented approach emphasizes harm reduction and medical evaluation rather than unsupervised cycling. Clinicians typically recommend: obtaining baseline and follow-up measurements including morning serum total and free testosterone, LH/FSH, estradiol, prolactin, complete blood count (for hematocrit), fasting lipids, liver function tests, blood pressure logs, and cardiometabolic screening (glucose or HbA1c). If symptoms suggest hypogonadism, further assessment may include thyroid function and evaluation for alternative causes. Persistent symptoms or abnormal labs warrant referral to endocrinology and, when indicated, structured testosterone replacement or other evidence-based interventions.
It is also important to address legal and ethical considerations, but clinically the priority is risk mitigation. If a person plans discontinuation after prolonged AAS exposure, the goal is to ensure endocrine recovery, monitor cardiovascular health, support mental well-being, and evaluate fertility. Patients should be warned that abrupt changes can precipitate mood symptoms and fatigue. Sleep, nutrition, and supervised training adjustments can help, but they do not substitute for medical monitoring.
In summary, long-term anabolic steroid use can suppress the HPG axis, causing hypogonadism after cessation; it can elevate cardiovascular and hepatic risks through adverse metabolic effects; and it can contribute to mood and anxiety symptoms through neuroendocrine perturbations. Comprehensive follow-up using objective laboratory and clinical assessments is essential to identify complications early and guide individualized management. Source: [@zivass] (as cited in the provided Source Link)
Vass: @LaSueur_off @TheNotoriousMMA Dit il après 5 ans de cure de stéroïdes. J’espère tellement que Max va l’envoyer à la retraite. #breaking
— @zivass May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
